Research Paper Volume 13, Issue 13 pp 17407—17427

Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways

class="figure-viewer-img"

Figure 3. MBZ effectively inhibits cell wound healing/migration and induces apoptosis in the human CR ovarian cancer cells. (A) Cell wounding/migration assay. Freshly subconfluent OVCAR8CR (a) and SKOV3CR (b) cells were wounded with micro-pipette tips and treated with the indicated concentrations of MBZ. The wounding gaps were recorded at 0 h, 24 h and 40 h after MBZ treatment. Each assay condition was done in triplicate. Representative results are shown (B) Cell apoptosis assay. Subconfluent OVCAR8CR (a) and SKOV3CR (b) cells were treated with the indicated concentrations of MBZ. At 72 h after treatment, cells were collected, fixed and stained with Hoechst 33258 and examined under a fluorescence microscope. Representative images are shown. Representative apoptotic cells are indicated by arrows. (C) The expression of apoptosis-inducing genes. Subconfluent OVCAR8CR (a) and SKOV3CR (b) cells were treated with the indicated concentrations of MBZ for 48 h. Total RNA was isolated and subjected to qPCR analysis of the expression of CASP3 and BAX. GAPDH was used as the reference gene. All assays were done in triplicate. *p < 0.05, **p < 0.01, compared with that of the cells treated with 0 μM MBZ (i.e., DMSO solvent control) group.